TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02283164

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hazardous materials online education and study feedback
Description: Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
Study: NCT01156207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300mg Aliskiren qd for 6 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren
Description: 300mg Aliskiren qd for 6 month
Study: NCT03699449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib+cediranib combination therapy
Description: Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib combination therapy
Description: Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab + chemotherapy treatment
Description: Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab + tremelimumab + chemotherapy treatment
Description: Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab + tremelimumab + paclitaxel treatment
Description: Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab +chemotherapy treatment
Description: Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)
Study: NCT02283164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hazardous materials online education and study feedback
Description: Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
Study: NCT00907127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Diet (Metabolic Fitness Program)
Description: 6 month program of diet and exercise training and support.
Study: NCT00609466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 75mg IR 4 - 6 hourly Total: 72 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 30 mg IR 4 - 6 hourly Total: 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; 4 - 6 hourly; Total: 72 hours
Study: NCT03317665

Intervention type: DEVICE
Intervention: Mesh for hernia repair
Description: Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
Study: NCT03538119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training Program
Description: The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training Program
Description: The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants.
Study: NCT01756872

Intervention type: PROCEDURE
Intervention: Measurements of ovarian reserve
Description: Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
Study: NCT03036241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional angioplasty
Description: Angioplasty with conventional balloon
Study: NCT01825980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZF961
Description: There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00695708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program
Description: Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogpack
Description: Computer-aided cognitive program for cognitive abilities
Study: NCT02541448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiQuest AIRSEAL® Insufflation System (AIS)
Description: The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiQuest AIRSEAL® Insufflation System (AIS)
Description: The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization.
Study: NCT04744610

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Add 4-hour delayed radiographs
Description: Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
Study: NCT00168324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Study: NCT03036241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty with drug-eluting balloon
Description: Angioplasty with drug-eluting balloon
Study: NCT04559971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride for s.c. injection
Study: NCT02667171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised COPD Rehabilitation (control group)
Description: The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online COPD rehabilitation (experimental)
Description: Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group.
Study: NCT04070586

Intervention type: DEVICE
Intervention: 4DCBCT images
Description: Images are acquired and assessed offline
Study: NCT02435654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
Study: NCT04734314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
Study: NCT02727361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI : Magnetic Resonance Imaging
Description: Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
Study: NCT00361569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2041a
Description: 1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2041b
Description: 2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
Study: NCT02594631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic treatment
Description: Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
Study: NCT02123888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography
Description: Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
Study: NCT00711581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gallbladder retraction
Description: The gallbladder will be retracted using the Endograb retractor
Study: NCT00332241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, once daily, 8 weeks
Study: NCT04667780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablet 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 care
Description: As per the hospital guidelines

Intervention type: DRUG
Group type: OTHER
Intervention: Standard COVID-19 care
Description: As per the hospital guidelines
Study: NCT04030624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Electronic Patient Monitoring
Description: The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
Study: NCT00493350

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: 1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
Study: NCT03015896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03577223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Eggs
Description: 3 whole eggs per day for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg White-Based Egg Substitute
Description: 3-egg equivalent of egg white-based egg substitute per day for 4 weeks
Study: NCT04455633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211 low dose
Description: 11-week assessment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211 high dose
Description: 11-week assessment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX9211 Placebo
Description: 11-week assessment period
Study: NCT03606915

Intervention type: BEHAVIORAL
Intervention: pain evaluation
Description: collect CSF during spinal anesthesia

Intervention type: BEHAVIORAL
Intervention: pain evaluation
Description: collect CSF during spinal anesthesia

Intervention type: BEHAVIORAL
Intervention: pain evaluation
Description: collect CSF during spinal anesthesia
Study: NCT01593319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local injection (fascia iliaca block) using 150 mg ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natrium chloride
Description: Placebo injection of Natrium chloride solution
Study: NCT02768545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg per day before and after transplant
Study: NCT03510676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NiTiDES
Study: NCT02125110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Study: NCT00281554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSD1235
Description: IV
Study: NCT02405559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
Study: NCT04413838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIVOLUMAB
Description: IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection

Intervention type: OTHER
Group type: OTHER
Intervention: Routine standard of care
Description: No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
Study: NCT04734314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vojta therapy
Description: Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week.
Study: NCT02592421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: SGLT2 inhibitor (dapagliflozin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02143349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coleus forskohlii extract
Description: Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
Study: NCT04004143

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study: NCT01878162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00270257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Description: Oral tablet
Study: NCT02238626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for MN-166)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: Patient is given 50 mg riluzole twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: riluzole
Description: Patient is given 50 mg riluzole twice daily.
Study: NCT03531398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic test meal challenge
Description: Metabolic test meal challenge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic test meal challenge
Description: Metabolic test meal challenge
Study: NCT03205930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-MASCT
Description: The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
Study: NCT01222286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101
Description: 0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
Study: NCT02143349

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of 250 mg placebo capsule twice a day for 12 weeks
Study: NCT01555866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: IV
Study: NCT00168324

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Study: NCT01555866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: IV
Study: NCT01562340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate juice
Description: Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate fruit extract
Description: Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
Study: NCT00481078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02369432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy
Study: NCT03204019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur and Temozolomide
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur and Temozolomide combined with Thalidomide
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)